Condition: ARDS (Moderate or Severe) · AHRF · Mechanically Ventilated ICU Patients · Sponsor: Lungpacer Medical Inc.
Multi-center, randomized, controlled, open-label Phase 2 feasibility trial. Subjects on mechanical ventilation (MV) for acute hypoxemic respiratory failure (AHRF) with lung injury (including subjects who meet criteria for acute respiratory distress syndrome (ARDS)) will be randomized 2:1 to diaphragm neurostimulation-assisted ventilation (DNAV) using the AeroNova System plus lung-protective ventilation (Treatment) vs. lung-protective ventilation alone (Control).
This description comes directly from the study's public registry record.
Megan Cotts · (612) 986-7172 · mcotts@lungpacer.com
STARI Study · (484) 350-4530 · STARIstudy@lungpacer.com
Always discuss trial participation with your own doctor first.
| University of California San Diego | La Jolla, California, United States | Recruiting |
| Louisiana State University Health Sciences | Shreveport, Louisiana, United States | Recruiting |
| Wake Forest University School of Medicine | Winston-Salem, North Carolina, United States | Enrolling By Invitation |
| Cleveland Clinic | Cleveland, Ohio, United States | Recruiting |
| Temple University | Philadelphia, Pennsylvania, United States | Recruiting |
| Prisma Health | Columbia, South Carolina, United States | Recruiting |
| University Health Network (UHN) | Toronto, Ontario, Canada | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06832306